$Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study$

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study

•Darinaparsin demonstrated clinically meaningful efficacy (ORR: 19.3%) in patients with relapsed or refractory PTCL.•Darinaparsin was well tolerated, and safety was clinically acceptable and manageable. [Display omitted] Darinaparsin is a novel organic arsenical compound of dimethylated arsenic conj...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2023-09, Vol.7 (17), p.4903-4912
Hauptverfasser:	Kim, Won-Seog, Fukuhara, Noriko, Yoon, Dok-Hyun, Yamamoto, Kazuhito, Uchida, Toshiki, Negoro, Eiju, Izutsu, Koji, Terui, Yasuhito, Nakajima, Hideaki, Ando, Kiyoshi, Suehiro, Youko, Kang, Hye Jin, Ko, Po-Shen, Nagahama, Fumiko, Sonehara, Yusuke, Nagai, Hirokazu, Tien, Hwei-Fang, Kwong, Yok-Lam, Tobinai, Kensei
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trials and Observations
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!